tranexamic acid has been researched along with Angioedemas, Hereditary in 30 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Angioedemas, Hereditary: Inherited disorders that are characterized by subcutaneous and submucosal EDEMA in the upper RESPIRATORY TRACT and GASTROINTESTINAL TRACT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrum of bradykinin angioedemas." | 5.05 | [Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment]. ( Armengol, G; Boccon-Gibod, I; Bouillet, L; Coppo, P; Defendi, F; Du-Thanh, A; Fain, O; Gobert, D; Hardy, G; Javaud, N; Jeandel, PY; Launay, D; Panayotopoulos, V; Pelletier, F, 2020) |
| " We describe a case of a patient with HAE who had previously been refused surgery for tonsillitis due to the potential for oedema, in whom regular monitoring of C1-INH levels combined with intensified therapy with danazol, tranexamic acid and C1-INH concentrate enabled an uncomplicated procedure with no oedema crisis." | 3.78 | Successful management of hereditary angioedema during tonsillectomy: a case report. ( Hermans, C; Lambert, C; Vander Vorst, S, 2012) |
| "During the 2 years, there were 2,368 hereditary angioedema attacks among 169 patients (85%)." | 2.87 | Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial. ( Adnet, F; Baker, E; Bertrand, P; Boccon-Gibod, I; Bouillet, L; Coppere, B; Durand-Zaleski, I; Fain, O; Floccard, B; Gompel, A; Javaud, N; Kanny, G; Lapostolle, F; Launay, D; Martin, L; Mezaour, M; Petrovic, T; Rabetrano, H; Reuter, PG; Sobel, A; Vicaut, E; Woimant, M, 2018) |
| "In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point." | 2.75 | Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. ( Aberer, W; Anné, S; Arcoleo, F; Banerji, A; Bas, M; Bernstein, JA; Bier, H; Björkander, J; Bork, K; Bouillet, L; Bracho, F; Bull, C; Cicardi, M; Cillari, E; Dong, L; Fan, WT; Farkas, H; Feighery, C; Fernández Romero, DS; Floccard, B; Gleich, G; Grabbe, J; Greve, J; Hébert, J; Hoffmann, TK; Hurewitz, D; Jacobson, KW; Kaatz, M; Katelaris, CH; Keith, P; Kirkpatrick, CH; Kivity, S; Knolle, J; Kravec, I; Kreuz, W; Langton, D; Levy, RJ; Luger, T; Lumry, W; Malbrán, A; Martin, L; Maurer, M; Merk, H; Obtulowicz, K; Pichler, C; Reshef, A; Resnick, D; Riedl, M; Ritchie, B; Rosen, K; Rosenkranz, B; Schmid-Grendelmeier, P; Sitkauskiene, B; Smith, WB; Toubi, E; Werner, S; Wombolt, D; Yang, W; Zanichelli, A; Zimmermann, J, 2010) |
| "Although pregnancy has been considered a trigger, it may have variable effect on frequency of attacks of HAE." | 1.72 | Management of pregnancy in hereditary angioedema in a resource constrained setting: Our experience at Chandigarh, North India. ( Barman, P; Chawla, S; Chopra, S; Jindal, AK; Kaur, A; Longhurst, H; Mahajan, S; Sikka, P; Singh, S; Tyagi, R, 2022) |
| "Dysbiosis was restored after regular use of danazol or tranexamic acid." | 1.72 | Gut microbiome alterations in hereditary angioedema. ( Cao, Y; Kan, H; Wang, X; Zhi, Y, 2022) |
| "With a potentially early onset, hereditary angioedema (HAE) requires special knowledge also in infancy and early childhood." | 1.46 | Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema. ( Aabom, A; Andersen, KE; Bygum, A; Fagerberg, C; Fisker, N; Jakobsen, MA, 2017) |
| "Information on F12 mutation hereditary angioedema (HAE) is still limited, but Spain is now recognized as having one of the highest concentrations of cases in Western Europe." | 1.43 | Hereditary angioedema with F12 mutation: Clinical features and enzyme polymorphisms in 9 Southwestern Spanish families. ( Alcaraz, C; Bobadilla-González, P; Fernández-Vieira, L; García-Lozano, R; González-Quevedo, T; Hinojosa, B; Piñero-Saavedra, M; Saenz de San Pedro, B, 2016) |
| "We aimed to study the subgroups of hereditary angioedema with FXII mutation (FXII-HAE), unknown genetic defect (U-HAE) and idiopathic non-histaminergic acquired angioedema (InH-AAE)." | 1.42 | Characterization of patients with angioedema without wheals: the importance of F12 gene screening. ( Bafunno, V; Barca, MP; Del Giacco, SR; Firinu, D; Manconi, PE; Margaglione, M; Santacroce, R; Vecchione, G, 2015) |
| "More than half of the patients felt that hereditary angioedema had a significant psychological impact on their lives and restricted their physical activities." | 1.40 | Hereditary angioedema - consequences of a new treatment paradigm in Denmark. ( Bygum, A, 2014) |
| "C1 Inhibitor deficiency is a rare disorder, characterised by recurrent angio-oedema of skin, upper respiratory and gastrointestinal tracts." | 1.39 | Recurrent angio-oedema--three cases of C1 inhibitor deficiency. ( Chandini, R; Neeraj, M; Philip, A; Shajith, S; Soopy, K; Thulseedharan, NK, 2013) |
| "The prevalence of hereditary angioedema (HAE) is estimated to be approximately 1 case per 50000 persons in English literatures." | 1.37 | [National prevalence survey of hereditary angioedema in Japan]. ( Hide, M; Ikezawa, Z; Iwamoto, K; Mihara, S, 2011) |
| "It differs from hereditary angioedema caused by C1 inhibitor deficiency." | 1.35 | Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. ( Bork, K; Hardt, J; Staubach, P; Witzke, G; Wulff, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 22 (73.33) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jindal, AK | 1 |
| Barman, P | 1 |
| Chawla, S | 1 |
| Kaur, A | 1 |
| Tyagi, R | 1 |
| Sikka, P | 1 |
| Chopra, S | 1 |
| Mahajan, S | 1 |
| Longhurst, H | 2 |
| Singh, S | 1 |
| Cao, Y | 1 |
| Kan, H | 1 |
| Wang, X | 1 |
| Zhi, Y | 1 |
| Bouillet, L | 7 |
| Fain, O | 5 |
| Armengol, G | 2 |
| Aubineau, M | 1 |
| Blanchard-Delaunay, C | 1 |
| Dalmas, MC | 1 |
| De Moreuil, C | 1 |
| Du Thanh, A | 1 |
| Gobert, D | 2 |
| Guez, S | 1 |
| Hoarau, C | 1 |
| Jaussaud, R | 1 |
| Jeandel, PY | 3 |
| Maillard, H | 1 |
| Marmion, N | 1 |
| Masseau, A | 1 |
| Menetrey, C | 1 |
| Ollivier, Y | 2 |
| Pelletier, F | 2 |
| Plu-Bureau, G | 1 |
| Sailler, L | 1 |
| Vincent, D | 2 |
| Bouquillon, B | 1 |
| Verdier, E | 1 |
| Clerson, P | 1 |
| Boccon-Gibod, I | 6 |
| Launay, D | 5 |
| Norris, M | 1 |
| Ashoor, Z | 1 |
| Craig, T | 2 |
| Coppo, P | 1 |
| Defendi, F | 1 |
| Du-Thanh, A | 2 |
| Hardy, G | 1 |
| Javaud, N | 2 |
| Panayotopoulos, V | 1 |
| Iwamoto, K | 2 |
| Yamamoto, B | 1 |
| Ohsawa, I | 2 |
| Honda, D | 2 |
| Horiuchi, T | 1 |
| Tanaka, A | 1 |
| Fukunaga, A | 1 |
| Maehara, J | 1 |
| Yamashita, K | 1 |
| Akita, T | 1 |
| Hide, M | 2 |
| Mete Gökmen, N | 1 |
| Kuman Tunçel, O | 1 |
| Boğatekin, G | 1 |
| Bulut, G | 1 |
| Demir, S | 1 |
| Gelincik, A | 1 |
| Tunakan Dalgıç, C | 1 |
| Mungan, D | 1 |
| Zinser, E | 1 |
| Murad, A | 1 |
| Leahy, TR | 1 |
| Lenane, P | 1 |
| Durand-Zaleski, I | 1 |
| Gompel, A | 4 |
| Sobel, A | 1 |
| Woimant, M | 1 |
| Rabetrano, H | 1 |
| Petrovic, T | 1 |
| Lapostolle, F | 1 |
| Reuter, PG | 1 |
| Bertrand, P | 1 |
| Mezaour, M | 1 |
| Coppere, B | 1 |
| Floccard, B | 2 |
| Kanny, G | 2 |
| Baker, E | 1 |
| Martin, L | 3 |
| Vicaut, E | 1 |
| Adnet, F | 1 |
| Chamaraux-Tran, TN | 1 |
| Levy, F | 1 |
| Zappaterra, M | 1 |
| Goetz, J | 1 |
| Goichot, B | 1 |
| Steib, A | 1 |
| Bygum, A | 2 |
| Wintenberger, C | 1 |
| Farkas, H | 2 |
| Veszeli, N | 1 |
| Csuka, D | 1 |
| Temesszentandrási, G | 1 |
| Tóth, F | 1 |
| Kőszegi, L | 1 |
| Varga, L | 1 |
| Philip, A | 1 |
| Neeraj, M | 1 |
| Soopy, K | 1 |
| Shajith, S | 1 |
| Chandini, R | 1 |
| Thulseedharan, NK | 1 |
| Ponard, D | 1 |
| Fiorella, S | 1 |
| Drouet, C | 2 |
| Firinu, D | 1 |
| Bafunno, V | 1 |
| Vecchione, G | 1 |
| Barca, MP | 1 |
| Manconi, PE | 1 |
| Santacroce, R | 1 |
| Margaglione, M | 1 |
| Del Giacco, SR | 1 |
| Nagamachi, S | 1 |
| Hisada, A | 1 |
| Shimamoto, M | 1 |
| Inoshita, H | 1 |
| Mano, S | 1 |
| Tomino, Y | 1 |
| Deroux, A | 1 |
| Pralong, P | 1 |
| Pagnier, A | 1 |
| Djenouhat, K | 1 |
| Faisant, C | 1 |
| Piñero-Saavedra, M | 1 |
| González-Quevedo, T | 1 |
| Saenz de San Pedro, B | 1 |
| Alcaraz, C | 1 |
| Bobadilla-González, P | 1 |
| Fernández-Vieira, L | 1 |
| Hinojosa, B | 1 |
| García-Lozano, R | 1 |
| Yu, SK | 1 |
| Callum, J | 1 |
| Alam, A | 1 |
| Frank, MM | 1 |
| Zuraw, B | 1 |
| Banerji, A | 2 |
| Bernstein, JA | 2 |
| Busse, P | 1 |
| Christiansen, S | 1 |
| Davis-Lorton, M | 1 |
| Li, HH | 1 |
| Lumry, WR | 1 |
| Riedl, M | 2 |
| Aabom, A | 1 |
| Andersen, KE | 1 |
| Fagerberg, C | 1 |
| Fisker, N | 1 |
| Jakobsen, MA | 1 |
| Bork, K | 2 |
| Wulff, K | 1 |
| Hardt, J | 1 |
| Witzke, G | 1 |
| Staubach, P | 1 |
| Van Sickels, NJ | 1 |
| Hunsaker, RB | 1 |
| Van Sickels, JE | 1 |
| Vitrat-Hincky, V | 1 |
| Dumestre-Perard, C | 1 |
| Cesbron, JY | 1 |
| Lunardi, J | 1 |
| Massot, C | 1 |
| Cicardi, M | 1 |
| Bracho, F | 1 |
| Malbrán, A | 1 |
| Rosenkranz, B | 1 |
| Lumry, W | 1 |
| Aberer, W | 1 |
| Bier, H | 1 |
| Bas, M | 1 |
| Greve, J | 1 |
| Hoffmann, TK | 1 |
| Reshef, A | 1 |
| Ritchie, B | 1 |
| Yang, W | 1 |
| Grabbe, J | 1 |
| Kivity, S | 1 |
| Kreuz, W | 1 |
| Levy, RJ | 1 |
| Luger, T | 1 |
| Obtulowicz, K | 1 |
| Schmid-Grendelmeier, P | 1 |
| Bull, C | 1 |
| Sitkauskiene, B | 1 |
| Smith, WB | 1 |
| Toubi, E | 1 |
| Werner, S | 1 |
| Anné, S | 1 |
| Björkander, J | 1 |
| Cillari, E | 1 |
| Hurewitz, D | 1 |
| Jacobson, KW | 1 |
| Katelaris, CH | 1 |
| Maurer, M | 1 |
| Merk, H | 1 |
| Feighery, C | 1 |
| Gleich, G | 1 |
| Hébert, J | 1 |
| Kaatz, M | 1 |
| Keith, P | 1 |
| Kirkpatrick, CH | 1 |
| Langton, D | 1 |
| Pichler, C | 1 |
| Resnick, D | 1 |
| Wombolt, D | 1 |
| Fernández Romero, DS | 1 |
| Zanichelli, A | 1 |
| Arcoleo, F | 1 |
| Knolle, J | 1 |
| Kravec, I | 1 |
| Dong, L | 1 |
| Zimmermann, J | 1 |
| Rosen, K | 1 |
| Fan, WT | 1 |
| Mihara, S | 1 |
| Ikezawa, Z | 1 |
| Hermans, C | 1 |
| Vander Vorst, S | 1 |
| Lambert, C | 1 |
| Cole, SW | 1 |
| Lundquist, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hereditary Angioedema : Interest From the Use of a Call Center During the Attacks.[NCT01679912] | Phase 4 | 200 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Determination of Specific Biomarkers of Angioneurotic Crisis[NCT02833675] | 120 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care[NCT04978051] | Phase 2 | 73 participants (Actual) | Interventional | 2021-04-12 | Completed | ||
| Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)[NCT00500656] | Phase 3 | 85 participants (Actual) | Interventional | 2005-03-01 | Completed | ||
| Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema[NCT00097695] | Phase 3 | 84 participants (Actual) | Interventional | 2004-12-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least three consecutive measurements for all symptoms. (NCT00500656)
Timeframe: 48 hours
| Intervention | Hours (Median) |
|---|---|
| Randomized Controlled -Icatibant | 10.0 |
| Randomized Controlled-Tranexamic Acid | 51.0 |
The primary efficacy endpoint was Time to onset of symptom relief (TOSR) following treatment with either icatibant or tranexamic acid. The median time to onset of symptom relief for the icatibant group was compared to the the median time to onset of symptom relief for the tranexamic acid group. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe. (NCT00500656)
Timeframe: 2 days
| Intervention | Hours (Median) |
|---|---|
| Randomized Controlled -Icatibant | 2.0 |
| Randomized Controlled-Tranexamic Acid | 12.0 |
The time to almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least 3 consecutive measurements for all symptom. (NCT00097695)
Timeframe: 5 days
| Intervention | Hours (Median) |
|---|---|
| Randomized Control Trial-icatibant | 8.5 |
| Randomized Control Trial-placebo | 19.4 |
The primary efficacy endpoint was TOSR assessed by the patient using a Visual Analogue Scale (VAS). The VAS is a scale used to measure intensity of each symptom of the attack at baseline and at the pre-determined time points throughout treatment period. It consists of a horizontal 10cm line, with the 0 point corresponding to a state where patient experiences no symptoms at all and the 10cm point represents the worst symptoms ever experienced by patient. The patient indicates his/her current state of symptoms by drawing a mark across the horizontal line. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the 3 primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe. (NCT00097695)
Timeframe: 5 days
| Intervention | Hours (Median) |
|---|---|
| Randomized -Icatibant | 2.5 |
| Randomized -Placebo | 4.6 |
"This parameter assessed the time to regression (start of improvement) of observable(visible) symptoms according to the patients. Patients were asked Report date and time when you feel that your symptoms start to improve." (NCT00097695)
Timeframe: 5 days
| Intervention | Hours (Median) |
|---|---|
| Randomized -Icatibant | 0.8 |
| Randomized -Placebo | 16.9 |
5 reviews available for tranexamic acid and Angioedemas, Hereditary
| Article | Year |
|---|---|
Management of pediatric hereditary angioedema types 1 and 2: A search for international consensus.
Topics: Androgens; Angioedemas, Hereditary; Child; Complement C1 Inhibitor Protein; Hereditary Angioedema Ty | 2022 |
[Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment].
Topics: Angioedema; Angioedemas, Hereditary; Bradykinin; Chemoprevention; Comorbidity; Diagnosis, Differenti | 2020 |
Prophylactic Therapy for Hereditary Angioedema.
Topics: Androgens; Angioedemas, Hereditary; Clinical Decision-Making; Complement C1 Inhibitor Protein; Disea | 2017 |
Hereditary angioedema: treatment, management, and precautions in patients presenting for dental care.
Topics: Acute Disease; Adult; Airway Obstruction; Aminocaproic Acid; Androgens; Angioedemas, Hereditary; Ant | 2010 |
Icatibant for the treatment of hereditary angioedema.
Topics: Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Bradykinin Receptor An | 2013 |
2 trials available for tranexamic acid and Angioedemas, Hereditary
| Article | Year |
|---|---|
Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial.
Topics: Adult; Androgens; Angioedemas, Hereditary; Call Centers; Clinical Competence; Cluster Analysis; Emer | 2018 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Topics: Acute Disease; Adult; Angioedemas, Hereditary; Bradykinin; Bradykinin B2 Receptor Antagonists; Doubl | 2010 |
23 other studies available for tranexamic acid and Angioedemas, Hereditary
| Article | Year |
|---|---|
Management of pregnancy in hereditary angioedema in a resource constrained setting: Our experience at Chandigarh, North India.
Topics: Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Female; Humans; India; Pregnancy; Tranexam | 2022 |
Gut microbiome alterations in hereditary angioedema.
Topics: Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Danazol; Dysbiosis; Family; Gastrointestin | 2022 |
Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs.
Topics: Androgens; Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Humans; Progestins; Quality of | 2022 |
The diagnosis and treatment of hereditary angioedema patients in Japan: A patient reported outcome survey.
Topics: Adolescent; Adult; Aged; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Antifibri | 2021 |
Psychiatric and Clinical Characteristics of Hereditary Angioedema Patients Who Experienced Attacks During COVID-19.
Topics: Adult; Angioedemas, Hereditary; Anxiety; COVID-19; Danazol; Female; Humans; Male; Middle Aged; SARS- | 2021 |
Acute Genital Swelling Heralding C1 Esterase Inhibitor Deficiency in a Child.
Topics: Angioedemas, Hereditary; Child, Preschool; Complement C1 Inhibitor Protein; Diagnosis, Differential; | 2017 |
Cardiac surgery and C1-inhibitor deficiency.
Topics: Aged, 80 and over; Amines; Analgesics; Anesthesia; Angioedemas, Hereditary; Antifibrinolytic Agents; | 2014 |
Hereditary angioedema - consequences of a new treatment paradigm in Denmark.
Topics: Activities of Daily Living; Administration, Cutaneous; Adult; Aged; Angioedemas, Hereditary; Bradyki | 2014 |
Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients.
Topics: Adult; Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Female; Humans; Male; Middle Aged; | 2014 |
Management of pregnancies in a hereditary angioedema patient after treatment with attenuated androgens since childhood.
Topics: Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 Inhibitor Protein; Danazol; E | 2015 |
Recurrent angio-oedema--three cases of C1 inhibitor deficiency.
Topics: Abdominal Pain; Adolescent; Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 I | 2013 |
Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency.
Topics: Aged; Angioedema; Angioedemas, Hereditary; Antibodies, Blocking; Autoantibodies; Autoimmunity; Compl | 2015 |
Characterization of patients with angioedema without wheals: the importance of F12 gene screening.
Topics: Adolescent; Adult; Aged; Angioedema; Angioedemas, Hereditary; Antifibrinolytic Agents; Bradykinin; B | 2015 |
Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan.
Topics: Adrenal Cortex Hormones; Adult; Androgens; Angioedemas, Hereditary; Antifibrinolytic Agents; Complem | 2015 |
Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema.
Topics: Adolescent; Adult; Angioedemas, Hereditary; Bradykinin; Child; Complement C1 Inhibitor Protein; Cont | 2016 |
Hereditary angioedema with F12 mutation: Clinical features and enzyme polymorphisms in 9 Southwestern Spanish families.
Topics: Adolescent; Adult; Aminopeptidases; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
C1-esterase inhibitor for short-term prophylaxis in a patient with hereditary angioedema with normal C1 inhibitor function.
Topics: Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 Inactivator Proteins; Complem | 2016 |
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
Topics: Adolescent; Angioedemas, Hereditary; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agent | 2016 |
Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema.
Topics: Angioedemas, Hereditary; Child; Child, Preschool; Complement C4; Female; Genetic Testing; Humans; In | 2017 |
Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.
Topics: Adolescent; Adult; Age of Onset; Angioedemas, Hereditary; Child; Danazol; Factor XII; Female; Humans | 2009 |
Type III hereditary angio-oedema: clinical and biological features in a French cohort.
Topics: Angioedemas, Hereditary; Cohort Studies; Complement C1 Inactivator Proteins; Complement C1 Inhibitor | 2010 |
[National prevalence survey of hereditary angioedema in Japan].
Topics: Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Danazol; Humans; Japan; Prevalence; Tranex | 2011 |
Successful management of hereditary angioedema during tonsillectomy: a case report.
Topics: Adult; Angioedemas, Hereditary; Complement C1 Inhibitor Protein; Danazol; Edema; Female; Humans; Ton | 2012 |